News

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...
Medical Dialogues10h
CureVac announces resolution of patent litigation with Pfizer/BioNTech
CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA ...
The Peninsula Qatar4h
Pfizer, BioNTech reach Covid jab settlement with GSK, CureVac
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...
EU Scandal: EPPO Corruption Czar Kövesi Conceals 'Politically Inconvenient' Corruption
A whistleblower alleges that EU anti-fraud chief Laura Codruța Kövesi destroyed corruption evidence to protect political ...